Conference Coverage

Researchers find predictors of worse MS outcomes in post hoc study of three trials

Publish date: February 28, 2018

 

REPORTING FROM ACTRIMS FORUM 2018

“The challenge with this particular study is we took everybody,” Dr. Repovic added. Next he would like to look at only those participants who received fingolimod throughout the trials to see if any specific predictors emerge.

Dr. Repovic disclosed he is on the speakers bureau for Novartis, the company that sponsored the study.

SOURCE: Repovic P et al. Abstract P210.

Pages

Recommended Reading

Adil Harroud, MD
MDedge Neurology
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MS
MDedge Neurology
Nearly half of MS patients treated by primary docs miss out on meds
MDedge Neurology
Physicians often bypass cognition, depression screening in MS
MDedge Neurology
Study identifies characteristics that may constitute the MS prodrome
MDedge Neurology
Do Neurologists Adequately Screen Patients With MS for Cognitive Impairment and Depression?
MDedge Neurology
ECTRIMS and EAN Publish Recommendations for Treating MS
MDedge Neurology
Is MS caused by one-two punch of pinworm and Epstein-Barr virus?
MDedge Neurology
Extended-interval dosing of natalizumab linked to lower risk of PML
MDedge Neurology
Fingolimod switch from an injectable linked to improved outcomes in relapsing MS
MDedge Neurology